Bayesian methods in health economics

Bayesian Methods in Health Economics

Volumn , Issue , 2012, Pages 1-223

  Baio, Gianluca ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901757030     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13099     Document Type: Book

References (175)

1. Ades, A., K. Claxton, and M. Sculpher (2006). Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Economics 15, 373-381.
2. Ades, A., G. Lu, and K. Claxton (2004). Expected value of sample information calculations in medical decision modeling. Medical Decision-Making 24, 207-227.
3. Ades, A. and A. Sutton (2006). Multiparameter evidence synthesis in epidemiology and medical decision-making: Current approaches. Journal of the Royal Statistical Society A 169, 5-35.
4. Albert, J. (2007). Bayesian Computation with R. Springer-Verlag, New York, NY.
5. Arbuthnot, J. (1710). An argument for Divine Providence, taken from the constant regularity observed in the births of both sexes. Philosophical Transactions of the Royal Society of London 27, 186-190.
6. Baio, G. (2012). BCEA: A package to run Bayesian Cost-Effectiveness Analysis in R. https://sites.google.com/a/statistica.it/gianluca/bcea.
7. Baio, G. and P. Dawid (2011). Probabilistic sensitivity analysis in health economics. Statistical Methods in Medical Research doi: 0962280211419832, First published 18 September 2011.
8. Baio, G. and P. Russo (2009). A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes. Pharmacoeconomics 27 (8), 645-655.
9. Barber, J. and S. Thompson (1998). Analysis and interpretation of cost data in randomised controlled trials: Review of published studies. British Medical Journal 317, 1195-1200.
10. Bayes, T. (1763). Essay towards solving a problem in the doctrine of chances. Philosophical Transactions of the Royal Society of London 53, 370-418.
11. Bennet, K., G. Torrence, M. Boyle, and R. Guscot (2000). Cost-utility analysis in depression: The McSad utility measure for depression health states. Psychiatric Services 51(9), 1171-1176.
12. Berger, J. (1985). Statistical Decision Theory and Bayesian Analysis, 2nd edition. Springer-Verlag, New York, NY.
13. Bernardo, J. and A. Smith (1999). Bayesian Theory. John Wiley & Sons, New York, NY.
14. Berry, D. (1996). Statistics: A Bayesian Perspective. Duxbury, London, UK.
15. Bertsch McGrayne, S. (2011). The Theory That Would Not Die: How Bayes’ Rule Cracked the Enigma Code, Hunted Down Russian Submarines, and Emerged Triumphant from Two Centuries of Controversy. Yale University Press, New Haven, CT.
16. Berwick, D. (2005). Broadening the view of evidence-based medicine. International Journal of Quality and Safety in Health Care 14, 315-316.
17. Brazier, J. (2010). Is the EQ-5D fit for purpose in mental health? British Journal of Psychiatry 197, 348-349.
18. Brazier, J., J. Ratcliffe, A. Tsuchiya, and J. Salomon (2007a). Measuring and Valuing Health Benefits for Economic Evaluations. Oxford University Press, Oxford, UK.
19. Brazier, J., J. Roberts, and M. Deverill (2002). The estimation of a preferencebased measure of health from the SF-36. Journal of Health Economics 21(2), 271-292.
20. Brazier, J., J. Roberts, A. Tsuchiya, and J. Busschbach (2004). A comparison of the EQ-5D and the SF-6D across seven patient groups. Health Economics 13, 873-884.
21. Brazier, J., Y. Yang, and A. Tsuchiya (2007b). Review of Methods for Mapping between Condition Specific Measures onto Generic Measures of Health. Office of Health Economics, London, UK.
22. Brennan, A. and S. Kharroubi (2005). Efficient Computation of Partial Expected Value of Sample Information Using Bayesian Approximation. Research Report 560/05, Department of Probability and Statistics, University of Sheffield, UK.
23. Brennan, A., S. Kharroubi, A. O’Hagan, and J. Chilcott (2007). Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Medical Decision-Making 27, 448-470.
24. Briggs, A. (2000). Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 22, 479-500.
25. Briggs, A., A. Ades, and M. Price (2003). Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework. Medical Decision-Making 23, 341-350.
26. Briggs, A., R. Goeree, G. Blackhouse, and B. O’ Brien (2002). Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision-Making 4, 290-308.
27. Briggs, A. and A. Gray (1998). The distribution of health care costs and their statistical analysis for economic evaluation. Journal of Health Services Research and Policy 3, 233-245.
28. Briggs, A. and B. O’ Brien (2001). The death of cost-minimisation analysis? Journal of Health Economics 10, 179-184.
29. Briggs, A. and M. Sculpher (1998). Introducing Markov models for economic evaluation. Pharmacoeconomics 13(4), 397-409.
30. Briggs, A., M. Sculpher, and K. Claxton (2006). Decision Modelling for Health Economic Evaluation. Oxford University Press, Oxford, UK.
31. Brooks, S., A. Gelman, G. Jones, and X. Meng (2011). Handbook of Markov Chain Monte Carlo. Chapman & Hall/CRC, Boca Raton, FL.
32. Brouwer, W., L. Niessen, M. Postma, and F. Rutten (2005). Need for differential discounting of costs and health effects in cost-effectiveness analyses. British Medical Journal 331(7514), 446-448.
33. Browne, W. and D. Draper (2006). A comparison of Bayesian and likelihoodbased methods for fitting multilevel models. Bayesian Analysis 1(3), 473-517.
34. Carlin, B. and T. Louis (2009). Bayesian methods for data analysis 3rd edition. Chapman & Hall/CRC, Boca Raton, FL.
35. Christensen, R., W. Johnson, A. Branscum, and T. Hanson (2011). Bayesian Ideas and Data Analyses. Chapman & Hall/CRC, Boca Raton, FL.
36. Claxton, K. (1999a). Bayesian approaches to the value of information: Implications for the regulation of new pharmaceutical. Health Economics 8, 269-274.
37. Claxton, K. (1999b). The irrelevance of inference: A decision-making approach to stochastic evaluation of health care technologies. Journal of Health Economics 18, 342-364.
38. Claxton, K., L. Lacey, and S. Walker (2000). Selecting treatments: A decision theoretic approach. Journal of the Royal Statistical Society A 163, 211-225.
39. Claxton, K., P. Neumann, S. Araki, and M. Weinstein (2001). Bayesian valueof-information analysis. International Journal of Technology Assessment in Health Care 17, 38-55.
40. Claxton, K., M. Sculpher, C. McCabe, A. Briggs, R. Akehurst, M. Buxton, J. Brazier, and A. O’Hagan (2005). Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Economics 14, 339-347.
41. Congdon, P. (2001). Bayesian Statistical Modelling. John Wiley & Sons, Chichester, UK.
42. Congdon, P. (2003). Applied Bayesian Modelling. John Wiley & Sons, Chichester, UK.
43. Congdon, P. (2010). Applied Bayesian Hierarchical Methods. CRC Press, Boca Raton, FL.
44. Conigliani, C. and A. Tancredi (2009). A Bayesian model averaging approach for cost-effectiveness analysis. Health Economics 18(7), 807-821.
45. Cooper, N., P. Lambert, K. Abrams, and A. Sutton (2007). Predicting costs over time using Bayesian Markov Chain Monte Carlo methods: An application to early inflammatory polyarthritis. Health Economics 16, 37-56.
46. Cooper, N., A. Sutton, K. Abrams, D. Turner, and A. Wailoo (2004). Comprehensive decision analytical modelling in economic evaluation: A Bayesian approach. Health Economics 13(3), 203-226.
47. Cooper, N., A. Sutton, M. Mugford, and K. Abrams (2003). Use of Bayesian Markov Chain Monte Carlo methods to model cost-of-illness data. Medical Decision-Making, 23-38.
48. Coyle, D. and J. Oakley (2008). Estimating the expected value of partial perfect information: A review of methods. European Journal of Health Economics 9, 251-259.
49. Dawid, P. (1979). Conditional independence in statistical theory (with discussion). Journal of the Royal Statistical Society, B 41, 1-31.
50. Dawid, P. (2005). Probability and Proof. In T. Anderson, D. Schum, and W. Twining (Eds.), Analysis of Evidence-2nd Edition. Cambridge University Press, Cambridge, UK.
51. Dawson, J., H. Doll, C. Jenkinson, and A. Carr (2010). The routine use of patient reported outcome measures in healthcare settings. British Medical Journal 340, 464-467.
52. de Finetti, B. (1974). Theory of Probability, Volume 1. John Wiley & Sons, New York, NY.
53. Department of Health of the Commonwealth of Australia (1992). Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee, Including Submissions Involving Economic Analyses. Australian Government Publishing Service, Canberra, Australia.
54. Devlin, N., A. Tsuchiya, K. Buckingham, and C. Tilling (2011). A uniform time trade off method for states better and worse than dead: Feasibility study of the ‘lead time’ approach. Health Economics 20(3), 348-361.
55. Dolan, P., C. Gudex, P. Kind, and A. Williams (1995). A Social Tariff for Euroqol: Results from a UK general population survey. Centre for Health Economics, University of York, York, UK.
56. Donaldson, C. and K. Gerard (2005). The Economics of Health Care Financing: The Visible Hand. Palgrave MacMillan, New York, NY.
57. Doubilet, P., C. Begg, M. Weinstein, P. Braun, and B. McNeil (1985). Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Medical Decision-Making 5, 157-177.
58. Draper, D. (1995). Assessment and propagation of model uncertainty (with discussion). Journal of the Royal Statistical Society, B 57, 45-97.
59. Drummond, M., B. O’Brien, G. Stoddar, and G. Torrance (2005). Methods for the Economic Evaluation of Health Care Programmes. Third Edition. Oxford University Press, London, UK.
60. Eddy, D., V. Hasselblad, and R. Shachter (1990). A Bayesian method for synthesizing evidence: The confidence profile method. International Journal of Technology Assessment in Health Care 6, 31-55.
61. Edwards, D. (2000). Introduction to Graphical Modelling 2nd edition. Springer Verlag, New York, NY.
62. Felli, J. and G. Hazen (1998). Sensitivity analysis and the expected value of perfect information. Medical Decision-Making 18, 95-109.
63. Felli, J. and G. Hazen (1999). A Bayesian approach to sensitivity analysis. Health Economics 8, 263-268.
64. Fenwick, E., K. Claxton, and M. Sculpher (2001). Representing uncertainty: The role of cost effectiveness acceptability curves. Health Economics 10, 779-787.
65. Fenwick, E., B. O’Brien, and A. Briggs (2004). Cost-effectiveness acceptability curves — Facts, fallacies and frequently asked questions. Health Economics 13, 269-274.
66. Fenwick, E., S. Palmer, K. Claxton, M. Sculpher, K. Abrams, and A. Sutton (2006). An iterative Bayesian approach to health technology assessment: Application to a policy of preoperative optimization for patients undergoing major elective surgery. Medical Decision-Making 26, 480-496.
67. Fienberg, S. (2006). When did Bayesian inference become Bayesian? Bayesian Analysis 1, 1-40.
68. Folland, S., A. Goodman, and M. Stano (2012). The Economics of Health and Health Care. Seventh Edition. Prentice Hall, Upper Saddle River, NJ.
69. Gamerman, D. (1997). Markov Chain Monte Carlo. Chapman & Hall, London, UK.
70. Gelman, A. (2006). Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 1(3), 515-533.
71. Gelman, A., J. Carlin, H. Stern, and D. Rubin (2004). Bayesian Data Analysis -2nd edition. Chapman & Hall, New York, NY.
72. Gelman, A. and J. Hill (2007). Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge University Press, Cambridge, UK.
73. Gelman, A. and D. Rubin (1992). Inference from iterative simulation using multiple sequences. Statistical Sciences 7, 457-511.
74. Geman, S. and D. Geman (1984). Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images. IEEE Transactions on Pattern Analysis and Machine Intelligence 6, 721-741.
75. Gilks, W., S. Richardson, and D. Spiegelhalter (1996). Markov Chain Monte Carlo in Practice. Chapman & Hall, London, UK.
76. Gillies, D. (2000). Philophical theories of probability. Routledge, London, UK.
77. Girolami, M. and B. Calderhead (2011). Riemann manifold Langevin and Hamiltonian Monte Carlo methods. Journal of the Royal Statistical Society B 73(2), 1-37.
78. Glick, A., J. Doshi, S. Sonnad, and D. Polsky (2007). Economic Evaluation in Clinical Trials. Oxford University Press, Oxford, UK.
79. Goodman, S. (1999). Toward evidence-based medical statistics. 1: The P value fallacy. Annals of Internal Medicine 130, 995-1004.
80. Griffin, S., K. Claxton, N. Hawkins, and M. Sculpher (2006). Probabilistic analysis and computationally expensive models: Necessary and required? Value in Health 9, 244-252.
81. Hastings, W. (1970). Monte Carlo sampling methods using Markov Chains and their applications. Biometrika 57(1), 97-109.
82. Howard, R. (1966). Information value theory. IEEE Transactions on System Science and Cybernetics, (1) 22-26. SCC-2.
83. Howie, D. (2002). Interpreting Probability. Cambridge University Press, Cambridge, UK.
84. Hunnink, M. and P. Glasziou (2001). Decision-making in Health and Medicine. Cambridge University Press, Cambridge, UK.
85. Institute of Medicine (2008). Improving the Quality of Cancer Clinical Trials: Workshop Summary. The National Academies Press, Washington, DC.
86. Jackman, S. (2009). Bayesian Analysis for the Social Sciences. John Wiley & Sons, New York, NY.
87. Jackson, C., L. Boijke, S. Thompson, K. Claxton, and L. Sharples (2011). A framework for addressing structural uncertainty in decision models. Medical Decision-Making 31, 662-674.
88. Jackson, C., L. Sharples, and S. Thompson (2010). Structural and parameter uncertainty in Bayesian cost-effectiveness analysis. Journal of the Royal Statistical Society, C 59, 233-253.
89. Jackson, C., S. Thompson, and L. Sharples (2009). Accounting for uncertainty in health economic decision models by using model averaging. Journal of the Royal Statistical Society, A 172(2), 383-404.
90. Jeffreys, H. (1961). Theory of Probability. Clarendon Press, Oxford, UK.
91. Jordaan, I. (2005). Decisions under Uncertainty. Cambridge University Press, Cambridge, UK.
92. Karroubi, S., J. Brazier, J. Roberts, and A. O’Hagan (2007). Modelling sf-6d health state preference data using a nonparametric Bayesian method. Journal of Health Economics 26(3), 597-612.
93. Kind, P., R. Brooks, and R. Rabin (2005). EQ-5D Concepts and Methods: A Developmental History. Springer, Dordrecht, The Netherlands.
94. King, J., J. Tsevat, M. Lave, and J. Roberts (2005). Willingness to pay for a quality-adjusted life year: Implications for societal health care resources allocation. Medical Decision-Making 27, 667-677.
95. Koerkamp, B., M. Hunink, T. Stijnen, J. Hammitt, K. Kuntz, and M. Weinstein (2007). Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analyses. Medical Decision-Making 27 (2), 101-111.
96. Kruschke, J. (2011). Doing Bayesian Data Analysis. Academic Press, Burlington, MA.
97. Lancaster, T. (2008). An Introduction to Modern Bayesian Econometrics. Blackwell Publishing, Oxford, UK.
98. Laplace, P. (1774). Mémoires sur la probabilité des causes par les évènemens. Mémoires de mathématique et de physique presentés à l’Académie royale des sciences, par divers savs et lûs dans ses assemblées 6, 621-656.
99. Laplace, P. (1812). Thorie Analytique des Probabilités. Veuve Courcier, Paris, France.
100. Lean, M., J. Mann, J. Hoek, R. Elliot, and G. Schofield (2008). Translational research: From evidence-based medicine to sustainable solutions for public health problems. British Medical Journal, 337.
101. Lee, P. (2004). Bayesian Statistics, 3rd edition. Arnold, London, UK.
102. Lindley, D. (1972). Bayesian Statistics, A Review. SIAM, Montpelier, VT.
103. Lindley, D. (1985). Making Decisions (2nd edition). John Wiley & Sons, London, UK.
104. Lindley, D. (2000). The philosophy of statistics. The Statistician 49, 293-337.
105. Lindley, D. (2006). Understanding Uncertainty. John Wiley & Sons, New York, NY.
106. Loomes, G. and L. McKenzie (1989). The use of QALYs in health care decision making. Social Science and Medicine 28, 299-308.
107. Luce, B. and A. O’Hagan (2003). A Primer on Bayesian Statistics in Health Economics and Outcome Research. Bayesian Initiative in Health Economics and Outcome Research.
108. Lunn, D., D. Spiegelhalter, A. Thomas, and N. Best (2009). The BUGS project: Evolution, critique and future directions. Statistics in Medicine 28(25), 3049-3067.
109. McIntosh, E., P. Clarke, E. Frew, and J. Louviere (2010). Applied Methods of Cost-Benefit Analysis in Health Care. Oxford University Press, Oxford, UK.
110. Meltzer, M. and S. Teutsch (1998). Setting priorities for health needs and managing resources. In D. Stroup and S. Teutsch (Eds.), Statistics in Public Health: Quantitative Approaches to Public-Health Problems. Oxford University Press, New York, NY.
111. Metropolis, N., A. Rosenbluth, M. Rosenbluth, A. Teller, and E. Teller (1953). Equations of state calculations by fast computing machines. Journal of Chemical Physics 21(6), 1087-1092.
112. Miller, K. and S. Homan (1994). Determining transition probabilities: Confusion and suggestions. Medical Decision-Making 14, 52-58.
113. Mood, A., F. Graybill, and D. Boes (1993). Introduction to the Theory of Statistics. McGraw-Hill, New York, NY.
114. Morris, S., N. Devlin, and D. Parkin (2007). Economic Analysis in Health Care. John Wiley & Sons, Chichester, UK.
115. Mortimer, D. and L. Segal (2007). Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Medical Decision-Making 28, 66-89.
116. Neal, R. (2003). Slice sampling. Annals of Statistics 31(3), 705-767.
117. Negrín, M. and F. Vàzquez-Polo (2008). Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach. Journal of Health Economics 27, 1250-1259.
118. NICE (2008). Guide to the Methods of Technology Appraisal. National Institute for Health and Clinical Excellence, London, UK.
119. NICE (2011). Our Guidance. National Institute for Health and Clinical Excellence, London, UK.
120. Nixon, R. and S. Thompson (2005). Incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Economics 14, 1217-1229.
121. Ntzoufras, I. (2009). Bayesian Modelling Using WinBUGS. John Wiley & Sons, New York, NY.
122. Oakley, J. (2009). Decision-theoretic sensitivity analysis for complex computer models. Technometrics 51(3), 121-129.
123. Oakley, J. and A. O’Hagan (2004). Probabilistic sensitivity analysis of complex models: A Bayesian approach. Journal of the Royal Statistical Society B 66(3), 751-769.
124. O’Brien, B. and A. Briggs (2002). Analysis of uncertainty in health care cost-effectiveness studies: An introduction to statistical issues and methods. Statistical Methods in Medical Research 11, 455-468.
125. O’Hagan, A. (1994). Bayesian Inference, volume 2B Kendall’s Advanced Theory of Statistics. Arnold, London, UK.
126. O’Hagan, A., C. Mc Cabe, R. Akehurst, A. Brennan, A. Briggs, K. Claxton, E. Fenwick, D. Fryback, M. Sculpher, D. Spiegelhalter, and A. Willan (2004). Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 23, 539-536.
127. O’Hagan, A. and J. Stevens (2001). A framework for cost-effectiveness analysis from clinical trial data. Health Economics 10, 303-315.
128. O’Hagan, A. and J. Stevens (2003). Assessing and comparing costs: How robust are the bootstrap and methods based on asymptotic normality? Health Economics 12, 33-49.
129. O’Hagan, A., J. Stevens, and J. Montmartin (2000). Inference for the costeffectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 17, 339-349.
130. O’Hagan, A., J. Stevens, and J. Montmartin (2001). Bayesian cost effectiveness analysis from clinical trial data. Statistics in Medicine 20, 733-753.
131. O’Hagan, A., M. Stevenson, and J. Madan (2006). Monte Carlo probabilistic sensitivity analysis for patient level simulation models: Efficient estimation of mean and variance using ANOVA. Health Economics.
132. Pareek, M., J. Watson, L. Ormerod, O. Kon, G. Woltmann, P. White, I. Abubakar, and A. Lalvani (2011). Screening of immigrants in the UK for imported latent tuberculosis: A multicentre cohort study and costeffectiveness analysis. Lancet Infections Diseases 11, 435-444.
133. Parmigiani, G. (2002a). Measuring uncertainty in complex decision analysis models. Statistical Methods in Medical Research 11, 513-537.
134. Parmigiani, G. (2002b). Modeling in Medical Decision-Making. John Wiley & Sons, New York, NY.
135. Petrillo, J. and J. Cairns (2008). Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Review Pharmacoeconomics Outcomes Research 8(5), 453-461.
136. Plummer, M. (2010). JAGS: Just Another Gibbs Sampler. http://www-fis.iarc.fr/~martyn/software/jags/.
137. Price, M. and A. Briggs (2002). Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 20(3), 183-194.
138. Raftery, A. and S. Lewis (1995). The number of iterations, convergence diagnostics and generic metropolis algorithms. In W. Gilks, S. Richardson, and D. Spiegelhalter (Eds.), Practical Markov Chain Monte Carlo. Chapman & Hall, London, UK.
139. Raiffa, H. (1968). Decision Analysis-Introductory Lectures on Choices under Uncertainty. Addison Wesley, Reading, MA.
140. Raiffa, H. and H. Schlaifer (1961). Applied Statistical Decision Theory. Harvard University Press, Boston, MA.
141. Robert, C. (2001). The Bayesian Choice-2nd edition. Springer Verlag, New York, NY.
142. Robert, C. and G. Casella (2004). Monte Carlo Statistical Methods-2nd edition. Springer Verlag, New York, NY.
143. Robert, C. and G. Casella (2010). Introducing Monte Carlo Methods with R. Springer Verlag, New York, NY.
144. Robert, C. and G. Casella (2011). A short history of Markov Chain Monte Carlo: Subjective recollections from incomplete data. Statistical Science 26, 102-115.
145. Rowen, D. and J. Brazier (2011). Technical Document 11: Alternatives to EQ-5D for Generating Health State Utility Values. NICE Decision Support Unit, London, UK.
146. Rue, H., S. Martino, and N. Chopin (2009). Approximate Bayesian inference for latent Gaussian models using integrated nested Laplace approximations (with discussion). Journal of the Royal Statistical Society B 71, 319-392.
147. Rushby, J. and J. Cairns (2005). Economic Evaluation. Open University Press, Maidenhead, UK.
148. Saltelli, A., S. Tarantola, F. Campolongo, and M. Ratto (2004). Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models. John Wiley & Sons, Chichester, UK.
149. Savage, L. (1954). The Foundations of Statistics. Dover Publications, New York, NY.
150. Sculpher, M., K. Claxton, M. Drummond, and C. McCabe (2006). Whither trial-based economic evaluation for health decision making? Health Economics 15, 677-687.
151. Senn, S. (2003). Dicing with Death. Cambridge University Press, Cambridge, UK.
152. Smith, J. (1988). Decision Analysis: A Bayesian approach. Chapman & Hall, London, UK.
153. Smith, J. (2011). Bayesian Decision Analysis: Principles and Practice. Cambridge University Press, Cambridge, UK.
154. Sonneberg, F. and J. Beck (1993). Markov models in medical decision-making: A practical guide. Medical Decision-Making 13(4), 322-338.
155. Spiegelhalter, D., K. Abrams, and J. Myles (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. John Wiley & Sons, Chichester, UK.
156. Spiegelhalter, D. and A. Barnett (2009). London murders: A predictable pattern? Significance 6 (1), 5-8.
157. Spiegelhalter, D. and N. Best (2003). Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Statistics in Medicine 22, 3687-3709.
158. Spiegelhalter, D., N. Best, B. Carlin, and A. van der Linde (2002). Bayesian measures of model complexity and fit (with discussion). Journal of the Royal Statistical Society B 64(4), 583-639.
159. Spiegelhalter, D., A. Thomas, and N. Best (2002). WinBUGS version 1.4. MRC Biostatistics Unit, Cambridge, UK.
160. Stinnett, A. and J. Mullahy (1998). Net health benefits: A new framework for the analysis of uncertainty in cost effectiveness analysis. Medical Decision-Making 18 (Suppl), S68-S80.
161. Strong, M., J. Oakley, and J. Chilcott (2011). Managing structural uncertainty in health economic decision models: A discrepancy approach. Journal of the Royal Statistical Society C 61, 25-45.
162. Sturtz, S., U. Ligges, and A. Gelman (2005). R2WinBUGS: A package for running WinBUGS from R. Journal of Statistical Software 12(3), 1-16. http://www.jstatsoft.org.
163. Su, Y. and M. Yajima (2010). R2jags User manual: A Package to call jags from R. http://www.cran.r-project.org/web/packages/R2jags/R2jags.pdf.
164. Thomas, A., B. O’Hara, U. Ligges, and S. Sturtz (2012). Package BRugs manual. http://cran.r-project.org/web/packages/BRugs/BRugs.pdf.
165. Thompson, S. and R. Nixon (2005). How sensitive are cost-effectiveness analysis to choice of parametric distributions? Medical Decision-Making 14, 421-428.
166. van der Gaag, M., A. Stant, K. Wolters, E. Buskens, and D. Wiersma (2011). Cognitive-behavioural therapy for persistent recurrent psychosis in people with schizophrenia-spectrum disorder: Cost-effectiveness analysis. British Journal of Psychiatry 198, 59-65.
167. van Hout, B., M. Gordon, and F. Rutten (1994). Costs, effects and C/E ratios alongside a clinical trial. Health Economics 3, 309-319.
168. van Rossum, L., vanRijn A., A. Verbeek, M. Oijen, R. Laheij, P. Fockens, J. J. E. Adang, and E. Dekker (2011). Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: A cost effectiveness analysis. International Journal of Cancer 128, 1908-1917.
169. Venables, W. and Smith, D. and The R Development Core Team. An Introduction to R. http://cran.r-project.org/doc/manuals/R-intro.pdf.
170. von Neumann, J. and O. Morgenstein (1953). Theory of Games and Economic Behaviour. Third Edition. John Wiley & Sons, New York, NY.
171. Whittaker, J. (1990). Graphical Models in Applied Multivariate Statistics. John Wiley & Sons, New York, NY.
172. Willan, A. and A. Briggs (2006). The Statistical Analysis of Cost-Effectiveness data. John Wiley & Sons, Chichester, UK.
173. Willan, A., A. Briggs, and J. Hock (2004). Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics 13, 461-475.
174. Wonderling, D., A. Vickers, R. Grieve, and R. McCarney (2004). Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. British Medical Journal 328(7442), 747-752.
175. Woodworth, G. (2004). Biostatistics: A Bayesian Introduction. John Wiley & Sons, New York, NY. World Health Organisation. Definition of Health. https://apps.who.int/aboutwho/en/definition.html.